Gender Dysphoria Clinical Trial
Official title:
Acoustic and Perceptual Effects of Intonation Training in Gender Diverse People
The aim of this project is to investigate the short- and the longer-term effect of intonation training on vocal characteristics, listener perceptions and patient related outcome measures (PROMS) in gender diverse people using a randomized sham-controlled trial.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | October 26, 2026 |
Est. primary completion date | October 26, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Normal hearing (using ISO standard audiometry) - Native Dutch speaker Exclusion Criteria: - A history of neurological disorders - Previous phonosurgery or speech therapy - Vocal pathology (using videolaryngostroboscopy) - Smokers. |
Country | Name | City | State |
---|---|---|---|
Belgium | Ghent University | Ghent | East Flanders |
Lead Sponsor | Collaborator |
---|---|
University Ghent |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in general intonation shift (Hz and ERB) | The general intonation shift is the mean size of the general increase or decrease of the fundamental frequency during the utterance. For the calculation of this parameter, the first and last vowel of the sentence were selected and the fo of the vowels were determined. Subsequently, the general intonation shift was calculated as the difference between start and end fo. Based on the size of this difference, the general intonation shift was categorized as an upward, downward or flat intonation shift. A difference smaller than 1.570884399 ERB was considered as a flat intonation shift. Finally, the percentage of upward, downward and flat intonation shifts could be determined. | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 20 min.) | |
Primary | Change in final intonation shift (Hz and ERB) | The Final intonation shift indicates the average size of the upward or downward intonation shift at the end of the utterance. This parameter was calculated as the difference between the fo at the beginning of the final rise or drop and the fo at the end. The beginning was located on the last stressed vowel and the end of the final rise or drop was located on the last unstressed vowel. In case that the utterance ended with a stressed vowel, the intonation shift was derived from the difference in fo within this vowel. | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 20 min.) | |
Primary | Change in general pitch range (Hz and ERB) | This parameter was calculated as the difference between the minimum (5th percentile) and the maximum fo (95th percentile) of the utterance. For this calculation the "Intonantion and stress trajectory" script was used (Corthals, 2019a; Van Borsel, Vandaele, & Corthals, 2013). | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 20 min.) | |
Primary | Change in pitch variation index (Hz/s and ERB/s) | This parameter was determined by the sum of the absolute value of all pitch changes during the utterance between percentile 5 and 95 divided by the total duration of the utterance. The pitch variation index reflects the size and speed of the intonation maneuvers. For this parameter the script "Intonation and stress trajectory" was used (Corthals, 2019a; Van Borsel, Vandaele, & Corthals, 2013). | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 20 min.) | |
Primary | Gender perception of the voice | A listening experiment with femininity ratings using a visual analogue scale (VAS: very feminine - neutral - very masculine). | During a listening experiment (+/- 40 minutes). | |
Primary | Change in patient's satisfaction with their voice - VAS | Visual analoge scales investigating the client's satisfaction of the therapy and psychosocial functioning:
examples: My speech fits who I am (don't agree at all - neutral - completely agree) How masculine/feminine do you sound while speaking? (very masculine - gender ambiguous (neutral) - very feminine) While speaking, there is a wide variation of my pitch. (don't agree at all - neutral - completely agree) (3) I sound more feminine/male/neutral compared to before the training period. (don't agree at all - neutral - completely agree) After the training period, my pitch range increased (I can produce higher and/or lower tones). (don't agree at all - neutral - completely agree)) |
baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Primary | Change in patient's satisfaction with their voice - TWVQ | Trans Women Voice Questionnaire: 30 questions investigating trans women's experiences with their voice (1 = never or seldom; 2 = sometimes; 3 = often; 4 = usual or always). The score can range from 30 to 120. A lower score indicates higher satisfaction with the voice. | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Primary | Change in patient's satisfaction with their voice - VHI | Voice Handicap Index: 30 questions investigating the impact of voice on the quality of life (0 = never; 1 = almost never; 2 = sometimes; 3 = almost always; 4 = always) . The score can range from 30 to 120. A lower score indicates higher satisfaction with the voice. | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Secondary | Change in speech fundamental frequency (SFF) | median speech fundamental frequency (SFF) | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Secondary | Change in formant frequency 1 (F1) | F1 of the vowels /a/, /i/ and /u/ | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Secondary | Change in formant frequency 2 (F2) | F2 of the vowels /a/, /i/ and /u/ | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Secondary | Change in formant frequency 3 (F3) | F3 of the vowels /a/, /i/ and /u/ | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Secondary | Change in formant frequency 4 (F4) | F4 of the vowels /a/, /i/ and /u/ | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) | |
Secondary | Change in formant frequency 5 (F5) | F5 of the vowels /a/, /i/ and /u/ | baseline (before treatment) - at the end of the treatment period (after 4 weeks) - 4 (and 8) weeks after the end of the treatment period (after 8 (and 12) weeks (each measurement +/- 5 min.) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06098781 -
Gynaecological Gender-affirming Surgeries
|
||
Recruiting |
NCT04064671 -
ZEPHYR: A Study Evaluating Surgical Outcome After Implantation of the Zephyr ZSI 475 FTM Inflatable Penile Implant in the Neophallus After Female-to-male Sex Reassignment Surgery
|
||
Completed |
NCT03602222 -
An LGBT-Competency Program for Mental Health Professionals in Romania
|
N/A | |
Completed |
NCT04708600 -
Effectiveness of Speech Therapy in Trans Women.
|
N/A | |
Completed |
NCT04195659 -
Chest Dysphoria in Transmasculine Spectrum Adolescents
|
||
Not yet recruiting |
NCT05903911 -
Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria
|
N/A | |
Not yet recruiting |
NCT04265885 -
Gender Dysphoria and Transition
|
||
Not yet recruiting |
NCT04160364 -
Gender Dysphoria in Children and Adolescents : Parents' Perspectives
|
||
Recruiting |
NCT06245681 -
Effects of Cross-sex Hormone Treatment on Cardiac Function, Myocardial and Hepatic Fat Content
|
||
Active, not recruiting |
NCT05489159 -
Sleep and IR in Transgender Adolescents
|
||
Recruiting |
NCT04736797 -
Transition in Transgender
|
||
Recruiting |
NCT04979338 -
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
|
Phase 3 | |
Recruiting |
NCT05829928 -
Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy
|
||
Recruiting |
NCT04993469 -
Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery
|
N/A | |
Recruiting |
NCT05884307 -
Trans Care: An Online Intervention to Reduce Symptoms of Gender Dysphoria
|
N/A | |
Recruiting |
NCT05883553 -
Epithesis Versus Prosthesis in Post-phalloplasty Transgender Patients.
|
N/A | |
Completed |
NCT04290286 -
i2TransHealth: Interdisciplinary, Internet-based Trans Health Care
|
N/A | |
Terminated |
NCT03078829 -
The Relation of GnRH Treatment to QTc Interval in Transgender Females
|
||
Recruiting |
NCT05649605 -
Early Mental Response - The EMRE Study
|
N/A | |
Recruiting |
NCT06291675 -
Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content
|